ArticleInternational journal of clinical pharmacy2026
Cost-effectiveness of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China and the United States healthcare systems.
Junhao Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.